

Androgen Therapy
Aveed (testosterone undecanoate injectable)
Effective 09/01/2025

Plan	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Medical Benefit Pharmacy Benefit	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	Additional agents from this class are available through the pharmacy benefit. Please see the MassHealth Drug List for coverage and criteria.		

Overview

Aveed (testosterone undecanoate injectable) is indicated for testosterone replacement in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Coverage Guidelines

Authorization may be granted for new members to the plan who are currently receiving treatment with Aveed excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members diagnosed with any of following conditions when all the criteria are met, and documentation is provided:

Delayed Puberty

1. Diagnosis of delayed puberty
2. Prescriber is a pediatric endocrinologist or consult notes from a specialist are provided
3. Member is \geq 14 years of age and $<$ 17 years of age
4. **ONE** of the following:
 - a. Tanner staging of I or II for sexual maturation ratings
 - b. Other physical signs of delayed puberty such as: arm span exceeding the member's height by $>$ 5 cm, abnormal testicular growth (testicular volume $<$ 4 mL), bone ages documented as less than the member's current age
5. Low testosterone level provided via medical records or written on PA with dates drawn and reference ranges ($<$ 300 ng/dL total serum testosterone)* *Please note, provided levels should be drawn within one year of testosterone request.*
6. Inadequate response (defined as \geq 90 days of therapy) or adverse reaction to **BOTH** of the following:
 - a. testosterone cypionate intramuscular injection
 - b. testosterone enanthate intramuscular injection

Other Indications

1. **ONE** of the following:

- a. Diagnosis of **ONE** of the following:
 - i. gender dysphoria (gender identity disorder)
 - ii. transgenderism
 - iii. therapy after gender reassignment surgery
- b. **BOTH** of the following:
 - i. Diagnosis of **ONE** of the following:
 1. Primary hypogonadism
 2. Hypogonadotropic hypogonadism
 - ii. Low testosterone level provided via medical records or written on PA with dates drawn and reference ranges (< 300 ng/dL total serum testosterone)* *Please note, provided levels should be drawn within one year of testosterone request.*

2. Inadequate response (defined as ≥ 90 days of therapy) or adverse reaction to **BOTH** of the following:
 - a. testosterone cypionate intramuscular injection
 - b. testosterone enanthate intramuscular injection

Continuation of Therapy

Delayed Puberty

Recertifications beyond six months require documentation of low testosterone levels after discontinuation of therapy.

Other Indications

Resubmission by prescriber will infer a positive response to therapy.

Limitations

1. Initial and reauthorization approvals will be granted for:
 - a. Delayed puberty: 6 months
 - b. All other indications: 12 months.

References

1. Aveed (testosterone undecanoate) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Inc; Aug 2021

Review History

07/21/2021- Reviewed at July P&T; switched from CVS standard criteria to custom criteria; moved gender criteria from compendial to FDA indication; added reauth criteria for hypogonadism

11/16/2022 – Reviewed for Nov P&T. Separated out MH vs Comm/Exch. No clinical changes.

10/09/2024 – Reviewed and updated for P&T. Adopted MH criteria for Aveed. Effective 11/12/24

8/13/25 – Reviewed and updated for P&T. Part of annual UM review. Reference updated. No clinical changes. Effective 9/1/25

